Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 20 studies | 32% ± 11% | |
conventional dendritic cell | 16 studies | 33% ± 12% | |
macrophage | 16 studies | 26% ± 8% | |
dendritic cell | 10 studies | 33% ± 16% | |
monocyte | 10 studies | 34% ± 9% | |
non-classical monocyte | 9 studies | 20% ± 4% | |
myeloid cell | 9 studies | 29% ± 10% | |
epithelial cell | 6 studies | 32% ± 10% | |
neutrophil | 5 studies | 31% ± 10% | |
mononuclear phagocyte | 5 studies | 31% ± 8% | |
CD8-positive, alpha-beta T cell | 5 studies | 24% ± 7% | |
megakaryocyte | 4 studies | 41% ± 16% | |
intermediate monocyte | 4 studies | 34% ± 14% | |
goblet cell | 4 studies | 22% ± 6% | |
hematopoietic precursor cell | 3 studies | 26% ± 3% | |
common myeloid progenitor | 3 studies | 19% ± 4% | |
basal cell | 3 studies | 26% ± 4% | |
fibroblast | 3 studies | 22% ± 5% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 28% ± 9% | |
intestinal crypt stem cell | 3 studies | 22% ± 4% | |
CD4-positive, alpha-beta T cell | 3 studies | 31% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 8711.42 | 226 / 226 | 100% | 121.04 | 406 / 406 |
bladder | 100% | 3030.86 | 21 / 21 | 100% | 163.49 | 503 / 504 |
stomach | 100% | 5045.29 | 358 / 359 | 100% | 140.13 | 286 / 286 |
intestine | 100% | 3706.41 | 965 / 966 | 100% | 156.11 | 526 / 527 |
pancreas | 100% | 4032.44 | 328 / 328 | 99% | 77.22 | 177 / 178 |
skin | 100% | 6602.57 | 1808 / 1809 | 99% | 93.41 | 469 / 472 |
brain | 99% | 2859.14 | 2607 / 2642 | 100% | 152.25 | 705 / 705 |
esophagus | 99% | 3515.04 | 1425 / 1445 | 100% | 167.29 | 183 / 183 |
ovary | 98% | 1769.89 | 177 / 180 | 100% | 134.18 | 430 / 430 |
breast | 99% | 3670.82 | 453 / 459 | 99% | 143.65 | 1108 / 1118 |
thymus | 99% | 2735.12 | 649 / 653 | 98% | 69.44 | 592 / 605 |
lung | 98% | 2807.25 | 566 / 578 | 99% | 120.78 | 1147 / 1155 |
kidney | 100% | 4827.28 | 89 / 89 | 96% | 86.64 | 869 / 901 |
prostate | 96% | 1881.45 | 236 / 245 | 98% | 61.12 | 493 / 502 |
adrenal gland | 100% | 21121.49 | 258 / 258 | 93% | 205.34 | 215 / 230 |
uterus | 83% | 1177.83 | 141 / 170 | 100% | 126.95 | 457 / 459 |
lymph node | 0% | 0 | 0 / 0 | 100% | 154.59 | 29 / 29 |
spleen | 100% | 5665.29 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 151.76 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 67.84 | 1 / 1 |
muscle | 100% | 5188.99 | 802 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 78.65 | 79 / 80 |
adipose | 97% | 4005.14 | 1167 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 6650.74 | 826 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 3995.53 | 875 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 58% | 935.44 | 780 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1902445 | Biological process | regulation of mitochondrial membrane permeability involved in programmed necrotic cell death |
GO_0002931 | Biological process | response to ischemia |
GO_0090201 | Biological process | negative regulation of release of cytochrome c from mitochondria |
GO_0032780 | Biological process | negative regulation of ATP-dependent activity |
GO_0010849 | Biological process | regulation of proton-transporting ATPase activity, rotational mechanism |
GO_1902686 | Biological process | mitochondrial outer membrane permeabilization involved in programmed cell death |
GO_0071277 | Biological process | cellular response to calcium ion |
GO_0006457 | Biological process | protein folding |
GO_0008637 | Biological process | apoptotic mitochondrial changes |
GO_0090324 | Biological process | negative regulation of oxidative phosphorylation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0051882 | Biological process | mitochondrial depolarization |
GO_0098528 | Biological process | skeletal muscle fiber differentiation |
GO_0046902 | Biological process | regulation of mitochondrial membrane permeability |
GO_0070266 | Biological process | necroptotic process |
GO_2001243 | Biological process | negative regulation of intrinsic apoptotic signaling pathway |
GO_2000276 | Biological process | negative regulation of oxidative phosphorylation uncoupler activity |
GO_0071243 | Biological process | cellular response to arsenic-containing substance |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0000413 | Biological process | protein peptidyl-prolyl isomerization |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005753 | Cellular component | mitochondrial proton-transporting ATP synthase complex |
GO_0005757 | Cellular component | mitochondrial permeability transition pore complex |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0003755 | Molecular function | peptidyl-prolyl cis-trans isomerase activity |
GO_0042277 | Molecular function | peptide binding |
GO_0005515 | Molecular function | protein binding |
GO_0016018 | Molecular function | cyclosporin A binding |
Gene name | PPIF |
Protein name | Peptidyl-prolyl cis-trans isomerase (PPIase) (EC 5.2.1.8) Peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIase F) (EC 5.2.1.8) (Cyclophilin D) (CyP-D) (CypD) (Cyclophilin F) (Mitochondrial cyclophilin) (CyP-M) (Rotamase F) |
Synonyms | CYP3 |
Description | FUNCTION: PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding . Involved in regulation of the mitochondrial permeability transition pore (mPTP) . It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated . In cooperation with mitochondrial p53/TP53 is involved in activating oxidative stress-induced necrosis . Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels (By similarity). Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis . . FUNCTION: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. . FUNCTION: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. . |
Accessions | ENST00000448165.1 ENST00000225174.8 [P30405-1] H0Y548 R4GN99 ENST00000472580.6 P30405 |